Clearmind Medicine (CSE: CMND) (FSE: CWY0) (OTC: CMNDF), a psychedelic drug company, has announced the third webinar in its Psychedelics for Alcoholism series. During this webinar, addiction specialist and world-renowned author Dr. Gabor Maté will talk on the effects of Alcohol Use Disorder, addition and trauma; the webinar will also discuss how Clearmind’s patented portfolio has potential to be an effective treatment. A retired Vancouver physician and a member of the Order of Canada, Maté has authored four books that have been translated into nearly 30 languages. His next book, “The Myth of Normal: Trauma, Illness and Healing in a Toxic Culture,” will be published in 2022. Other participants in the webinar include Clearmind CEO Adi Zuloff-Shani and Clearmind VP of business development Mark Haden.

To register for the webinar, visit https://ibn.fm/EHdNb 

For more information, visit https://ibn.fm/XDk3T

About Clearmind Medicine Inc.

Clearmind is a psychedelic pharmaceutical biotech company focused on the discovery and development of novel psychedelic-derived therapeutics to solve widespread and underserved health problems, including alcohol use disorder. Its primary objective is to research and develop psychedelic-based compounds and attempt to commercialize them as regulated medicines, foods or supplements. The company’s intellectual portfolio currently consists of four patent families. Clearmind intends to seek additional patents for its compounds whenever warranted and will remain opportunistic regarding the acquisition of additional intellectual property to build its portfolio. For more information about the company, visit www.ClearmindMedicine.com.

About InvestorWire

InvestorWire is the wire service that gives you more. From regional releases to global announcements presented in multiple languages, we offer the wire-grade dissemination products you’ll need to ensure that your next press release grabs the attention of your target audience and doesn’t let go. While our competitors look to nickel and dime you with hidden fees and restrictive word limits, InvestorWire keeps things transparent. We offer UNLIMITED Words on all domestic releases. While other wire services may provide a basic review of your release, InvestorWire helps you put your best foot forward with complimentary Press Release Enhancement.

With our competitors, the work is done the second your release crosses the wire. Not with InvestorWire. We include follow-up coverage of every release by leveraging the ever-expanding audiences of the 50+ brands that make up the InvestorBrandNetwork.

Get more out of your next press release with InvestorWire. It’s unlike anything you’ve seen before.

For more information, please visit https://www.InvestorWire.com

Please see full terms of use and disclaimers on the InvestorBrandNetwork website applicable to all content provided by IBN, wherever published or re-published: http://ibn.fm/Disclaimer

InvestorWire (IW)
8033 Sunset Blvd Suite 1037-IW
Los Angeles, CA 90046
310.299.1717 Office
www.InvestorWire.com
Editor@InvestorWire.com

InvestorWire is part of the InvestorBrandNetwork.